Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Sequential Infusion of Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor T-Cells: A Promising Treatment Strategy for Refractory Immune-Mediated Platelet Transfusion Refractoriness

Yunju Ma, Qingya Cui, Chunxiu Yang, Wei Cui, Mengyun Li, Zheng Li, Haiping Dai, Liqing Kang, Lei Yu, Zaixiang Tang, Jianxin Fu, Min Jiang, Depei Wu, Xiaowen Tang

Blood (2024) 144 (Supplement 1): 683.

https://doi.org/10.1182/blood-2024-209249

Published: 2024

Journal Articles

Safety and Efficacy of VA Combined with Modified BuCy Conditioning Regimen Followed By Allo-HSCT for High-Risk or Refractory/Relapsed Acute Lymphoblastic Leukemia : A Prospective, Single-Center, Single-Arm Clinical Trial

Xiaoqian Chen, Wei Cui, Qingya Cui, Zheng Li, Sifan Chen, Mengyun Li, Xuekai Li, Juan Chen, Yan Yu, Xin Zhang, Depei Wu, Xiaowen Tang

Blood (2024) 144 (Supplement 1): 270.

https://doi.org/10.1182/blood-2024-209163

Published: 2024

Journal Articles

Unleashing the Power of CD19 CAR-T in Relapsed AML: Findings from a Prospective Single-Center Clinical Trial

Jia Yin, Qingya Cui, Haiping Dai, Zheng Li, Liqing Kang, Wei Cui, Xiaopeng Tian, Xiaming Zhu, Lei Yu, Depei Wu, Xiaowen Tang

Blood (2024) 144 (Supplement 1): 4836.

https://doi.org/10.1182/blood-2024-207197

Published: 2024

Journal Articles

Bird Regimen Followed By Anti-BCMA CAR T-Cell Immunotherapy As First-Line Therapy for Newly Diagnosed Multiple Myeloma: A Prospective, Single-Arm, Phase 3 Trial

Yue Zhou, Juan Chen, Qingya Cui, Haiping Dai, Zheng Li, Jia Yin, Wei Cui, Mengyun Li, Xuekai Li, Xin Zhang, Feiran Gong, Xiaming Zhu, Liqing Kang, Lei Yu, Depei Wu, Xiaowen Tang

Blood (2024) 144 (Supplement 1): 3384.

https://doi.org/10.1182/blood-2024-199119

Published: 2024

Journal Articles

Chemotherapy-Free Induction with Venetoclax and Azacitidine, Followed By Tandem CD19/CD22 CAR-T Cell Therapy As First-Line Treatment in Newly Diagnosed High-Risk Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Prospective, Single-Center, Single-Arm, Phase 2 Trial

Mengyun Li, Qingya Cui, Xuekai Li, Wei Cui, Xiaoqian Chen, Yan Yu, Juan Chen, Xin Zhang, Liqing Kang, Lei Yu, Depei Wu, Xiaowen Tang

Blood (2024) 144 (Supplement 1): 4197.

https://doi.org/10.1182/blood-2024-207017

Published: 2024

Journal Articles

How to Improve the Efficacy of Venetoclax and Azacitidine（VA）for Newly Diagnosed Acute Myeloid Leukemia？a Prospective, Single-Center, Single-Arm, Phase 2 Trial for New Diagnosed AML

Xuekai Li, Mengyun Li, Wei Cui, Xiaoqian Chen, Yan Yu, Juan Chen, Xin Zhang, Qingya Cui, Depei Wu, Xiaowen Tang

Blood (2024) 144 (Supplement 1): 4284.

https://doi.org/10.1182/blood-2024-208981

Published: 2024

Journal Articles

VA Combined with Mbucy Conditioning Regimen Followed By Allo-HSCT Can Improve Survival of High-Risk AML Patients: A Prospective, Single-Center, Single-Arm Clinical Trial

Wei Cui, Xiaoqian Chen, Qingya Cui, Zheng Li, Sifan Chen, Mengyun Li, Xuekai Li, Juan Chen, Yan Yu, Depei Wu, Xiaowen Tang

Blood (2024) 144 (Supplement 1): 3493.

https://doi.org/10.1182/blood-2024-207083

Published: 2024

Journal Articles

Rituximab Improves Clinical Outcomes of CAR-T Therapy for r/r B-ALL Via Sensitizing Leukemia Cells to CAR-T-Mediated Cytotoxicity and Reducing CAR-T Exhaustion

Yangzi Li, Sining Liu, Qingya Cui, Lingling Liu, Zheng Li, Wei Cui, Mengyun Li, Xiaming Zhu, Liqing Kang, Lei Yu, Depei Wu, Xiaowen Tang

Blood (2023) 142 (Supplement 1): 6803.

https://doi.org/10.1182/blood-2023-184505

Published: 2023

Journal Articles

Efficacy and Safety of the Second CAR-T Therapy in Patients with Refractory/Relapsed Acute B-Cell Lymphoblastic Leukemia

Sining Liu, Qingya Cui, Zheng Li, Wei Cui, Mengyun Li, Huiying Qiu, Shengli Xue, Suning Chen, Zhengming Jin, Miao Miao, Yue Han, Ying Wang, Xiaming Zhu, Lei Yu, Depei Wu, Xiaowen Tang

Blood (2023) 142 (Supplement 1): 3491.

https://doi.org/10.1182/blood-2023-186718

Published: 2023

Journal Articles

BCMA Re-Emergence As a Prognostic Indicator of Clinical Relapse after Chimeric Antigen Receptor T-Cell Therapy (CART) in Multiple Myeloma

Aliya Rashid, William Wesson, Forat Lutfi, Muhammad Umair Mushtaq, Joseph P McGuirk, Al-Ola Abdallah, Wei Cui, Nausheen Ahmed

Blood (2023) 142 (Supplement 1): 6801.

https://doi.org/10.1182/blood-2023-182126

Published: 2023

Journal Articles

Chidamide Combined with a Modified Bu-Cy Conditioning Regimen Improves Survival in Patients with T-Cell Acute Lymphoblastic Leukemia/Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Xuanqi Cao, Zheng Li, Yanming Zhang, Qingya Cui, Yunju Ma, Mengyun Li, Sifan Chen, Jia Yin, Wei Cui, Jia Chen, Aining Sun, Huiying Qiu, Suning Chen, Zhengming Jin, Xiaming Zhu, De-Pei Wu, Xiaowen Tang

Blood (2023) 142 (Supplement 1): 6959.

https://doi.org/10.1182/blood-2023-185258

Published: 2023

Journal Articles

Hematological and Non-Hematological Toxicities in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Responded to Daratumumab, Pomalidomide, and Dexamethasone (DPd)

Polina Bellman, Wei Cui, Zahra Mahmoudjafari, Shebli Atrash, Barry Paul, Hamza Hashmi, Rajesh Banderudrappagari, Leyla O. Shune, Al-Ola Abdallah, Nausheen Ahmed

Blood (2022) 140 (Supplement 1): 8074–8075.

https://doi.org/10.1182/blood-2022-168450

Published: 2022

Journal Articles

Daratumumab,Pomalidomide and Dexamethasone (DPd) Versus Daratumumab, Velcade and Dexamethasone (DVd) in Previously Treated Daratumumab Naïve Relapsed Refractory Multiple Myeloma Patients

Evguenia Ouchveridze, Chandandeep Singh, Shebli Atrash, Barry Paul, Meera Mohan, Omar Alkharabsheh, Aimaz Afrough, Wei Cui, Zahra Mahmoudjafari, Al-Ola Abdallah, Hamza Hashmi

Blood (2022) 140 (Supplement 1): 7164–7165.

https://doi.org/10.1182/blood-2022-168368

Published: 2022

Journal Articles

Outcomes of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Responded to Daratumumab, Pomalidomide and Dexamethasone (DPd), Followed By High Dose Chemotherapy/Autologous Stem Cell Transplantation (HDCT/ASCT) Versus (DPd) Alone

Jayanshu Jain, Ghena Khasawneh, Hamza Hashmi, Meera Mohan, Zahra Mahmoudjafari, Wei Cui, Joseph P. McGuirk, Leyla O. Shune, Nausheen Ahmed, Al-Ola Abdallah, Shebli Atrash

Blood (2022) 140 (Supplement 1): 10587–10588.

https://doi.org/10.1182/blood-2022-165828

Published: 2022

Journal Articles

B- Cell Maturation Antigen (BCMA) Re-Emergence and Relapse Patterns Post-BCMA-Chimeric Antigen Receptor T Cell (CAR-T ) Therapy for Multiple Myeloma

William Wesson, Wei Cui, Muhammad Mushtaq, Rajat Bansal, Anurag K. Singh, Marc Hoffmann, Aung M Tun, Ramesh Balusu, Haitham Abdelhakim, Sunil H Abhyankar, Joseph P. McGuirk, Leyla O. Shune, Al-Ola Abdallah, Nausheen Ahmed

Blood (2022) 140 (Supplement 1): 12781–12783.

https://doi.org/10.1182/blood-2022-160437

Published: 2022

Journal Articles

Anti CD19 CART Therapy Following Allogenic Hematopoietic Stem Cell Transplantation Improved the Survival of Patients with BCR::ABL1 -like Acute Lymphoblastic Leukemia

Haiping Dai, Wei Cui, Hongjie Shen, Qian Wang, Jia Yin, Zheng Li, Depei Wu, Xiaowen Tang

Blood (2022) 140 (Supplement 1): 10345–10346.

https://doi.org/10.1182/blood-2022-166687

Published: 2022

Journal Articles

Outcomes of Patients Who Are BCMA (B-cell maturation Antigen) Directed Therapy (BDT) Exposed Vs BCMA Naïve in Penta-Relapsed Refractory Multiple Myeloma (RRMM)

Aytaj Mammadzadeh, Fulei Peng, Shebli Atrash, Hamza Hashmi, Meera Mohan, Omar Alkharabsheh, Aimaz Afrough, Wei Cui, Zahra Mahmoudjafari, Al-Ola Abdallah

Blood (2022) 140 (Supplement 1): 4277–4278.

https://doi.org/10.1182/blood-2022-165762

Published: 2022

Journal Articles

The genetic landscape of germline DDX41 variants predisposing to myeloid neoplasms

Peng Li, Sara Brown, Margaret Williams, Thomas White, Wei Xie, Wei Cui, Deniz Peker, Li Lei, Christian A. Kunder, Huan-You Wang, Sarah S. Murray, Jennie Vagher, Tibor Kovacsovics, Jay L. Patel

Blood (2022) 140 (7): 716–755.

https://doi.org/10.1182/blood.2021015135

Published: 2022

Includes: Supplemental data

Journal Articles

Haplo-Identical Non-Gene Editing CD7 CAR T-Cells Induced Bone Marrow and Extramedullary Remission in a Pediatric Patient with TP53 Mutated Relapsed and Refractory Early T-Cell Precursor Lymphoblastic Leukemia/Lymphoma after Haploidentical Hematopoietic Stem Cell Transplantation

Haiping Dai, Yang Lin, Huimin Meng, Qingya Cui, Wenjuan Zhu, Xiaowen Tang, Wei Cui, Depei Wu

Blood (2021) 138 (Supplement 1): 4817.

https://doi.org/10.1182/blood-2021-151587

Published: 2021

Journal Articles

Belantamab in Combination with Dexamethasone in Patients with Triple-Class Relapsed/Refractory Multiple Myeloma

Tahani Atieh, Shebli Atrash, Meera Mohan, Leyla Shune, Zahra Mahmoudjafari, Julie Quick, Justin Riffel, Joseph P. McGuirk, Ghulam Rehman Mohyuddin, Al-Ola Abdallah, Nausheen Ahmed, Wei Cui, Anne Wishna

Blood (2021) 138 (Supplement 1): 1642.

https://doi.org/10.1182/blood-2021-149791

Published: 2021

NARROW

Sequential Infusion of Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor T-Cells: A Promising Treatment Strategy for Refractory Immune-Mediated Platelet Transfusion Refractoriness

Safety and Efficacy of VA Combined with Modified BuCy Conditioning Regimen Followed By Allo-HSCT for High-Risk or Refractory/Relapsed Acute Lymphoblastic Leukemia : A Prospective, Single-Center, Single-Arm Clinical Trial

Unleashing the Power of CD19 CAR-T in Relapsed AML: Findings from a Prospective Single-Center Clinical Trial

Bird Regimen Followed By Anti-BCMA CAR T-Cell Immunotherapy As First-Line Therapy for Newly Diagnosed Multiple Myeloma: A Prospective, Single-Arm, Phase 3 Trial

Chemotherapy-Free Induction with Venetoclax and Azacitidine, Followed By Tandem CD19/CD22 CAR-T Cell Therapy As First-Line Treatment in Newly Diagnosed High-Risk Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Prospective, Single-Center, Single-Arm, Phase 2 Trial

How to Improve the Efficacy of Venetoclax and Azacitidine（VA）for Newly Diagnosed Acute Myeloid Leukemia？a Prospective, Single-Center, Single-Arm, Phase 2 Trial for New Diagnosed AML

VA Combined with Mbucy Conditioning Regimen Followed By Allo-HSCT Can Improve Survival of High-Risk AML Patients: A Prospective, Single-Center, Single-Arm Clinical Trial

Rituximab Improves Clinical Outcomes of CAR-T Therapy for r/r B-ALL Via Sensitizing Leukemia Cells to CAR-T-Mediated Cytotoxicity and Reducing CAR-T Exhaustion

Efficacy and Safety of the Second CAR-T Therapy in Patients with Refractory/Relapsed Acute B-Cell Lymphoblastic Leukemia

BCMA Re-Emergence As a Prognostic Indicator of Clinical Relapse after Chimeric Antigen Receptor T-Cell Therapy (CART) in Multiple Myeloma

Chidamide Combined with a Modified Bu-Cy Conditioning Regimen Improves Survival in Patients with T-Cell Acute Lymphoblastic Leukemia/Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Hematological and Non-Hematological Toxicities in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Responded to Daratumumab, Pomalidomide, and Dexamethasone (DPd)

Daratumumab,Pomalidomide and Dexamethasone (DPd) Versus Daratumumab, Velcade and Dexamethasone (DVd) in Previously Treated Daratumumab Naïve Relapsed Refractory Multiple Myeloma Patients

Outcomes of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Responded to Daratumumab, Pomalidomide and Dexamethasone (DPd), Followed By High Dose Chemotherapy/Autologous Stem Cell Transplantation (HDCT/ASCT) Versus (DPd) Alone

B- Cell Maturation Antigen (BCMA) Re-Emergence and Relapse Patterns Post-BCMA-Chimeric Antigen Receptor T Cell (CAR-T ) Therapy for Multiple Myeloma

Anti CD19 CART Therapy Following Allogenic Hematopoietic Stem Cell Transplantation Improved the Survival of Patients with BCR::ABL1 -like Acute Lymphoblastic Leukemia

Outcomes of Patients Who Are BCMA (B-cell maturation Antigen) Directed Therapy (BDT) Exposed Vs BCMA Naïve in Penta-Relapsed Refractory Multiple Myeloma (RRMM)

The genetic landscape of germline DDX41 variants predisposing to myeloid neoplasms

Haplo-Identical Non-Gene Editing CD7 CAR T-Cells Induced Bone Marrow and Extramedullary Remission in a Pediatric Patient with TP53 Mutated Relapsed and Refractory Early T-Cell Precursor Lymphoblastic Leukemia/Lymphoma after Haploidentical Hematopoietic Stem Cell Transplantation

Belantamab in Combination with Dexamethasone in Patients with Triple-Class Relapsed/Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only